Mylan And Biocon’s Semglee Insulin Glargine Approved In US
Product Deemed A Biologic By FDA; Launch May Be Imminent
Mylan and Biocon have received FDA approval for their Semglee insulin glargine product, with a path to market seemingly clear after Mylan emerged victorious in several recent patent-litigation challenges. Meanwhile, the firm continues to strive towards an interchangeability designation that would make it a much more valuable opportunity.
You may also be interested in...
While in possession of a token biosimilar portfolio and pipeline, Sanofi has made it clear that its R&D dollars are unlikely to be spent on biosimilars, six months after reshaping its pipeline by exiting diabetes and cardiovascular diseases research.
After receiving “positive feedback” from the US Food and Drug Administration on its biosimilar insulin glargine, Lannett plans to move forward with its development activity.
Mylan says it is now ready to launch its Semglee insulin glargine rival to Sanofi’s Lantus in the US upon FDA approval, after removing the final intellectual-property barriers by way of a favorable inter partes review decision.